EMT6 Syngeneic Breast Cancer Model
The EMT6 is a triple-negative mammary carcinoma with a less aggressive metastatic potential. EMT6 also expresses PD-L1, and adopts pulmonary metastasis readily upon implantation, making the EMT6 tumor model well suited for immune-oncology combination studies.
Mammary carcinomas are a type of cancer that features characteristics of lobular and ductal carcinoma; EMT6 is an immortal mouse mammary carcinoma cell line. The syngeneic mouse model was produced through hyperplastic mammary alveolar, nodule implantation of an exogenous mammary fat pad.
EMT6 was derived from the transplantable murine mammary carcinoma of a BALB/Ccrfl mouse, following the implantation of a hyperplastic mammary alveolar nodule. The resulting tumor was propagated in BALB/cKa mice and isolated from clonal expansion.
Used as a powerful immuno-oncology tool due to the favorable immune profile and responsiveness to immune checkpoint blockades. EMT6 syngeneic models are suitable for cytotoxic therapy along with immune-modulating agents.
For stage IV breast cancer, the standard of care is systemic drug therapies such as hormone therapy, chemotherapy, targeted drugs, immunotherapy and a combination of these. In some instances, surgery and radiation therapy may be useful.
Advantages of the EMT6 Tumor Model
Our EMT6 tumor model uses BALB/c mice, and reflects the tumorigenicity of metastatic mammary cancers, providing a valuable platform for drug discovery.
EMT6 is distinguished by high immunogenicity and rapid tumor kinetics, providing dynamic tumor environments to aid in your studies.
Fully Characterized Model
We have characterized EMT6 mouse mammary carcinoma in both syngeneic (flank) and orthotopic models.
Applying the EMT6 Tumor Model
Characterized by its immunocompetence and ability to mimic key aspects of tumor biology, the EMT6 tumor model has a variety of key applications in breast cancer studies such as drug discovery and development, exploring the microenvironments of tumors, studying radiotherapy, and other applications.
Developing Immunotherapeutic Approaches
The EMT6 tumor model is immunocompetent, therefore it can be employed in the study of drugs and their impact on the immune system, and to evaluate immunomodulatory therapies. Additionally used in preclinical evaluation, the EMT6 mouse model will aid in assessing efficacy and toxicity of drug candidates, determining optimal dosage regimens, and in the investigation of combination therapies.
Radiation therapy is considered a standard treatment method for numerous cancer types, the EMT6 tumor model enables investigation into the response of tumors to radiation treatment, studying radio resistance, and the advancement of radiotherapy efficacy. Contributing to the optimization of radiation treatment, and development of approaches to combat resistance to treatment.